Close Menu

Twist Bioscience Synthetic Controls for Respiratory Viruses

Jul 22, 2020

Twist Bioscience has added 16 new synthetic controls for common respiratory viruses with symptoms similar to COVID-19, including influenza H1N1, influenza H32N, influenza B, rhinovirus, enterovirus, and several human coronaviruses including a prevalent mutated strain of SARS-CoV-2 (D614G.)

Applications for the products include environmental testing, assay development and verification, and diagnostic test validation.

Twist's controls are designed based on specific viral variants, cover the full viral genomes and are sequence-verified. Controls for alternative viral variants are available as custom products. The firm said RNA synthetic controls should be delivered within two weeks of ordering.

More Like This

Sep 25, 2020

Seven Bridges RHEO Visual Interface for Multi-Omic Analysis

Seven Bridges has introduced the RHEO Visual Interface workflow automation tool for multi-omic analysis. RHEO can completely auto-generate a visual interface from a developer's automation script, and complements the existing command line interface for automations releases by the company last year. The interface minimizes the time and effort required to set up and run data-analysis workflows for biologists, particularly those who work with experimental data but do not have extensive training in workflow automation, Seven Bridges said. Additional benefits include installation-free use, automatic authentication, instant collaboration, comprehensive audit logs, versioning and 100 percent reproducibility, all within a secure and compliant cloud environment, the company added.

Sep 24, 2020

LabCorp Resolution ctDx Lung Assay

LabCorp has launched the Resolution ctDx Lung assay for patients with non-small cell lung cancer (NSCLC). The test will be run by Resolution Biosciences and detects actionable mutations associated with the disease in a standard blood sample. The firm said the test can provide valuable information to help select the most effective targeted treatments for individual patients. In addition, LabCorp noted that the test is covered by Medicare. 

Sep 23, 2020

CRISPR QC and Cardea Bio CRISPR-BIND

CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, and is built on Cardea's biology-gated transistors and an automated, high-throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.

CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.

Sep 23, 2020

Congenica COVID-19 Module

Congenica has added a COVID-19 module to its genomic analysis platform. The company said that the new add-on will support research into relationships between a patient's genome and COVID-19 infection risk, severity, and clinical outcomes. The module also helps researchers prioritize variants in curated genes based on Human Phenotype Ontology terms that suggest COVID-19 symptoms.  

Sep 23, 2020

Exagen Avise Vasculitis AAV

Exagen launched the Avise Vasculitis AAV test panel of individual analytes to assess and monitor anti-neutrophil cytoplasmic antibody-associated vasculitis. ANCA-associated vasculitis is characterized by vascular inflammation and damage, and early symptoms of the disease vary widely. Exagen's test is intended for use in patients suspected of small vessel diseases, such as granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. 

Sep 22, 2020

Bio-Techne RNA-Protein Co-Detection Assays

Bio-Techne has expanded its Advanced Cell Diagnostics-branded RNAscope technology with the release of RNA-Protein Co-Detection Assays. RNAscope technology is an advanced in situ hybridization assay that enables visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues. The codetection assays allow researchers to simultaneously examine gene expression specific to cell types and identify cellular sources of secreted proteins. The new workflow enables a wider range of IHC-validated antibodies to be combined with RNA ISH.

Sep 18, 2020

Bio-Rad Laboratories StarBright Violet 515 Dye for Flow Cytometry

Bio-Rad Laboratories has launched the StarBright Violet 515 (SBV515) dye, the first of a new range of fluorescent nanoparticles for flow cytometry. SBV515 has an excitation maximum at 401 nanometers and emission maximum of 516 nanometers, offering improved brightness to better resolve rare and low antigen density populations. It has a narrow emission profile to reduce spillover into neighboring filters and minimize excitation by other lasers, making it suitable for inclusion in multicolor panels. The dye is not susceptible to photobleaching, delivers high lot-to-lot reproducibility, and is stable at 4° C with no loss of signal, Bio-Rad said.

Sep 18, 2020

Akoya Biosciences Proxima Spatial Biology Platform

Akoya Biosciences this week launched the Proxima Spatial Biology Platform to integrate rapid image acquisition and secure data sharing in the cloud. The new software is designed to allow users to visualize and analyze whole-slide, multiplexed immunofluorescence images generated by Akoya's Phenoptics platform, and will soon be expanded to visualize and analyze ultra-high-plex images generated by Akoya's CODEX platform, enabling an integrated, flexible, and scalable solution from discovery to translational and clinical research, the company said.

Sep 18, 2020

RenalytixAI: KidneyIntelX

RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients. 

The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month. 

Sep 17, 2020

Sanford Burnham Prebys Coronascape Bioinformatics Platform

Sanford Burnham Prebys Medical Discovery Institute has introduced Coronascape, a specialized version of its Metascape bioinformatics platform designed for big-data analysis of SARS-CoV-2 and COVID-19 research. The La Jolla, California-based research institute said that Coronascape is meant to serve as a multiomics data clearinghouse for efforts to develop effective targets and therapies for the novel coronavirus. SBP developed the web-based Metascape portal in partnership with the Genomics Institute of the Novartis Research Foundation and the University of California, San Diego.

Sep 15, 2020

10x Genomics Chromium Single-Cell Multiome ATAC + Gene Expression

10x Genomics has launched its Chromium Single-Cell Multiome ATAC + Gene Expression solution.

Combining the assay for transposase-accessible chromatin using sequencing with gene expression profiling by RNA sequencing, the new product enables researchers to analyze both epigenetic programming and the transcriptome in the same cell.

Sep 15, 2020

Paradigm4 Reveal: Single Cell

Paradigm4 has introduced Reveal: Single Cell, an app to help biopharmaceutical companies manage and analyze large sets of single-cell data. Reveal: Single Cell, built on top of the bioinformatics firm's SciDB database management platform, supports multiomic analysis and association. Paradigm4 said that users can choose cells across multiple studies to evaluate tissue distribution, look for variance in response to treatment, and compare normal to diseased cells. The new app is an extension of Reveal, a translational informatics platform released in 2018.

Sep 14, 2020

Bianano Genomics Lineagen EpiPanel Dx Plus

Bionano Genomics' recent acquisition Lineagen has launched the EpiPanel Dx Plus, a laboratory-developed test for epilepsy-related conditions.

The proprietary gene panel is based on 223 genes selected from a literature review, including genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen. The test is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures and can predict the recurrence risk for other members of the family and allows for personalized treatment. It has an expected diagnostic yield of 30 percent.

Sep 10, 2020

NimaGen SARS-CoV-2 WGS Kit

NimaGen of Nijmegen, the Netherlands, has launched the EasySeq SARS-CoV-2 Whole Genome Sequencing Kit. It is based on a patented reverse complement PCR (RC-PCR) library preparation method that combines target amplification and indexing into a single closed-tube PCR step, reducing hands-on time and risk of cross contamination or sample mix up. The kit includes tiled RC-PCR primer and probe pools to cover 99 percent of the viral genome with more than 90 percent read uniformity. Also included are the RC-PCR mastermix, UDI indexes, and an AmpliClean Magnetic Bead Clean-up kit.

Sep 09, 2020

CRG COVID-19 Viral Beacon Platform

The Center for Genomic Regulation (CRG) in Barcelona has launched COVID-19 Viral Beacon, a platform that lets scientists analyze raw and consensus COVID-19 genomic data from the European Nucleotide Archive (ENA), Oxford Nanopore Technologies, Illumina, NCBI/SRA, and GISAID. Users can search for specific genetic variants and explore associated metadata.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.